[Cardiooncology: Current Aspects of Prevention of Anthracycline Toxicity].
Kardiologiia
; 56(12): 72-79, 2016 12.
Article
in Ru
| MEDLINE
| ID: mdl-28290807
ABSTRACT
Anthracyclines including doxorubicin, epirubicin, daunorubicin, aclarubicin are extensively used as chemotherapeutic agents for treatment of hematological and other malignancies. In cancer therapy anthracyclines are often used in combinations with other chemotherapeutic drugs and agents for molecularly targeted therapy. Anthracyclines are effective and powerful antineoplastic drugs with wide spectrum of application but active use of preparations of this group is limited because of such side effects as cardiotoxicity, myelotoxicity, thromboembolism, alopecia, etc. Cardiotoxicity is the most severe side effect of anthracycline administration. Clinical studies have shown that it is progressive and irreversible. Therefore, early detection and prevention of anthracycline cardiotoxicity has become an important trend in cardiology.
Key words
Search on Google
Collection:
01-internacional
Health context:
1_ASSA2030
/
2_ODS3
Database:
MEDLINE
Main subject:
Anthracyclines
/
Cardiotoxicity
/
Antibiotics, Antineoplastic
Type of study:
Screening_studies
Limits:
Humans
Language:
Ru
Journal:
Kardiologiia
Year:
2016
Document type:
Article